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Haemophilus influenzae type b (Hib) is a significant cause of meningitis and pneumonia 
among children under 5 years. A conjugate vaccine has been available since the mid-
1980s, leading to disease reductions well above what would be expected from direct 
protection of the vaccine alone. This indicates indirect effects provide substantial 
protection against Hib disease and are a function of population-level vaccine coverage. 
Indirect effects are rarely investigated because it requires large, cluster randomized trials; 
instead we used pre-post vaccine introduction studies to model these effects.  
Methods 
Three methods to perform this analysis were identified in the literature. Wolfson, et al. 
described a method to compare the observed disease reduction to the reduction expected 
only from direct effects, resulting in an indirect effect multiplier based on vaccine 
coverage. Samandari, et al. estimated a multiplier for the number of people effectively 
protected by vaccination using vaccine coverage and incidence rates before and after 
vaccination. Lastly, Adegbola, et al. used average ages of Hib infection and vaccination 
to calculate an alternative estimate of direct protection from vaccination. Eleven studies 
were used for the Wolfson and Samandari methods and three were used for the Adegbola 
method.  
Results 
All three methods suggest a robust indirect effect of Hib vaccine against disease, with > 
90% disease reduction predicted at only 70% coverage. Indirect effects were most 




from two to six others. Direct effects dominated at vaccine coverages above 60%. 
Validating these results against an infectious disease theoretical framework and a study 
that empirically examined indirect effects on an individual level confirmed the accuracy 
of our results.  
Conclusion 
Predicted protection varied between the methods, but all demonstrated the importance of 
indirect effects at low vaccine coverage. These results can be used to better estimate the 
expected disease reduction prior to beginning a vaccine program and can impact policy 
decisions regarding vaccination. The models used in this analysis can also be applied to 
other vaccines, such as pneumococcal conjugate vaccine.  
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Hib Disease Burden 
Haemophilus influenzae type b (Hib) is a bacterium that causes significant 
morbidity and mortality in children under the age of five years. Responsible for numerous 
syndromes such as pneumonia, meningitis, and epiglottitis, as well as non-invasive but 
common diagnoses such as otitis media, Hib was the leading cause of invasive bacterial 
disease worldwide before the introduction of effective vaccines [1, 2]. Hib is one of the 
six serotypes of Haemophilus influenzae (a-f) but is responsible for about 95% of all 
invasive disease caused by Haemophilus influenzae. It is spread through droplets in the 
air and colonizes the nasopharynx, where it can be spontaneously cleared, remain without 
causing symptoms, or invade the bloodstream and cause invasive infection [2]. 
The burden of disease is almost exclusively in children under five years (U5s), 
with about two-thirds of it concentrated in children under 18 months and relatively few 
cases in adults [1]. In the absence of vaccination, the median age of invasive disease is 6-
8 months; as with most infectious diseases, median age increases after vaccination 
programs are established as younger children, who make up the bulk of the cases, are 
immunized and the disease burden curve shifts [2, 3]. It was estimated that in 1990, Hib 
caused about 450,000 deaths worldwide in U5s, which declined to about 370,000 in 2000 
[4, 5]. This is a small proportion of the approximately 8 million cases of invasive Hib 
disease in U5s annually and does not accurately reflect the morbidity of Hib-related 
syndromes such as pneumonia and epiglottis, which have significantly lower mortality 
rates than meningitis [5]. Although pneumonia is the most common Hib-caused 




up to 20%. While many children live through their encounter with Hib meningitis, not 
many do so unscathed. Up to 30% of surviving children have various neurological 
sequelae including seizure disorders and hearing/vision loss, many of which are 
permanent [2]. 
Hib Conjugate Vaccine 
The introduction of the highly effective Hib conjugate vaccine in the 1980s has 
led to the virtual disappearance of invasive Hib disease (IHiD) in children U5s from 
developed nations, though certain disadvantaged populations, such as Native Americans 
and Australian aboriginals, still have higher rates of disease than the general population 
due to poverty-associated risk factors [6, 7]. While vaccine uptake in low- and middle- 
income countries has been slower, almost all countries have now introduced Hib vaccine, 
with many countries achieving routine immunization of birth cohorts. However, the 
elevated disease risk among disadvantaged populations also holds in these countries and 
is exacerbated by reduced vaccination of at-risk populations. This is notable as Hib cases 
and deaths are concentrated in resource-poor settings, where routine vaccine use was 
slower to take root, exacerbating pre-existing disparities within and between countries of 
different economic levels. In 2000, just ten countries, all in Asia or Africa, account for an 
estimated 61% of childhood Hib deaths [5]. 
Much of the hesitancy to pursuing routine vaccination in these countries was due 
to a number of factors, including cost and insufficient disease burden data. Hib is a 
notoriously difficult organism to culture in the best of lab conditions, so poor lab 
facilities in many of these countries artificially decreased the measured incidence rate of 




and specimens collected after treatment initiation are much less likely to successfully 
culture Hib. The WHO recommends three doses of Hib vaccine, either with all three 
doses administered in a primary series or a two dose primary series with a booster dose 
[1]. Inclusion in the pentavalent vaccine that also includes diphtheria, tetanus, pertussis, 
and hepatitis b vaccine has helped defray some of the costs of the high number of 
required doses through reduced cold chain capacity requirements and has also simplified 
introduction into routine vaccination programs. Additionally, vaccine probe trials, which 
compared all-cause incidence of meningitis and pneumonia in clusters randomized to Hib 
vaccine, in Indonesia and the Gambia have demonstrated that Hib is prevalent in these 
countries and mainly was not lab-confirmed due to difficulty in culturing Hib and 
widespread empiric antibiotic use [1, 8, 9]. Worldwide Hib deaths have declined by 
almost 50% in one decade, falling to fewer than 200,000 deaths in the year 2010 [4]. This 
is most likely due to increasing quality of health systems and wider vaccine use in high-
burden settings. 
The Hib vaccine provides almost complete protection against invasive Hib 
disease, with direct efficacy estimates ranging from 95-100% [2]. Additionally, the 
vaccine has been shown to provide excellent indirect protection in addition to direct 
protection, leading to the elimination of Hib-associated disease much faster than other 
childhood vaccine-preventable diseases [10, 11]. Vaccination programs rely on indirect 
protection to establish herd immunity, or the protection of unvaccinated people due to 
high vaccine coverage in the population as a whole [12]. These indirect effects start to 
build as vaccine coverage increases and are most pronounced at medium coverage levels; 




very high coverage, almost all children are being protected directly by vaccination. Some 
pathogens, such as measles, require 95% vaccine coverage to achieve disease elimination, 
but strong indirect effects leading to herd immunity have been seen even at Hib vaccine 
coverage levels as low as 40-50% [10, 13-17]. Herd protection is clearly an important 
factor in understanding the full benefit of a routine immunization programs and 
eliminating Hib disease, but few attempts have been made to quantify the indirect effects 
of Hib vaccine.  
Indirect Effects 
 Indirect effects can only be quantified in a few study designs.  Rather, they are 
assumed to be notable post hoc when observed disease reduction is greater than what 
would be expected from direct effects alone at that vaccine coverage level. Hib vaccine 
reduces the risk of nasopharyngeal colonization as well as the risk of disease. In addition 
to standard herd immunity effects, the reduction of nasopharyngeal colonization in 
vaccinated individuals may further protect unvaccinated individuals from transmission 
and colonization, leading to less disease and explaining the strong indirect effects seen 
with Hib vaccine [18-20]. While some research has focused on understanding the 
biological mechanism of indirect protection, there is a dearth of information about the 
exact size of indirect effects and how they affect population level disease dynamics. 
Within this limited body of literature, little work has been done to understand how 
indirect effects can fluctuate as vaccine coverage changes, though this research is 
becoming more widespread [16, 21].  
Much of the reticence to empirically investigate indirect effects can be attributed 




studies randomize groups of people to the Hib vaccine or placebo arm and can compare 
the rates of disease in the unvaccinated people on the vaccine arm to the rates in 
unvaccinated people in the placebo arm to arrive at an understanding of the level of 
indirect protection provided by the vaccine. Because the unit of analysis in these trials is 
the cluster and not the individual, they require a sample size inflation that can vastly 
increase the already sizeable cost of a clinical trial [22, 23]. Newer study designs, such as 
stepped wedge trials, have been developed to examine indirect effects of vaccination as in 
The Gambia with hepatitis B vaccine [24]. However these trials require substantially 
more time to fully roll out when compared to a typical parallel design, again increasing 
the cost of a clinical trial.  
 Ideally, it would be desirable to have empirical evidence of the level of indirect 
protection from Hib vaccine against IHiD to inform vaccine rollout policies, especially in 
resource-poor settings. Factoring in the indirect protection provided by a vaccine could 
help administrators estimate the true level of vaccine coverage necessary to reduce 
disease by a certain amount. An indirect effect multiplier could be included in the vaccine 
effective coverage formula (vaccine efficacy * vaccine coverage) to predict the disease 
reduction due to direct and indirect effects of the vaccine in a population with certain 
vaccine coverage levels. A multiplier of one would indicate that disease reduction was 
completely due to direct effects of the vaccine, whereas anything larger would suggest 
the involvement of indirect effects in protection against IHiD. This could make vaccine 
programs more cost-effective and also inform when supplemental vaccination campaigns 
might be necessary in a given setting, making distribution of costlier vaccines more 




countries have achieved uptake, but the ideal target vaccine coverage levels remain 
uncertain [1].  
Due to the lack of funding for and interest in quantifying indirect effects within a 
large trial, we chose to use observational studies already available in the literature to 
understand the varying levels of herd protection based on total U5 vaccine coverage. 
Using available studies can provide an answer in settings where it is infeasible to conduct 
a cluster randomized trial or stepped wedge trial while still allowing for the calculation of 
indirect effects using real-world data. These estimates are also necessary for etiological 
modeling work that incorporates vaccine effective coverage, which usually only estimate 
direct protection. Previously, the only studies that have specifically examined herd 
protection as a function of Hib vaccine coverage used primary data; the use of secondary 
data to evaluate Hib indirect effects as a function of coverage has not formally been 






 The studies used for this analysis were vaccine impact studies included in the 
literature review for Hib Global Burden of Disease (GBD) estimates currently being 
compiled at the Johns Hopkins University International Vaccine Access Center (IVAC). 
Watt et al previously published Hib GBD estimates in 2009 for the year 2000 utilizing 
data from 1980-2005 [5]. These are now being updated to reflect the increased uptake of 
Hib vaccine and changes in disease burden in the past 15 years. Using a comprehensive 
literature search, studies published from 2005 and onward were included in the updated 
estimates. Broad search criteria were used to identify relevant studies from six global 
databases (Medline, Embase, CAB Health, Cochrane, Pascal, and Biosis) and four 
regional databases (African Index Medicus, Index Medicus for the WHO Eastern 
Mediterranean region, Latin American and Caribbean Health Sciences Information, and 
Health Literature, Library, and Information Services). Studies used in the previous GBD 
estimates were manually screened to identify relevant impact studies published before the 
timeframe of the current literature review. Additionally, Google Scholar was searched for 
any Hib vaccine impact studies that were not captured in the literature reviews.  
Studies were identified as potentially relevant if they reported on Hib vaccine 
impact on any syndrome in children in an observational setting. Those presenting results 
from individually-randomized clinical trials were not included, as only the direct effect of 
the Hib vaccine could be assessed in these trials. More than 40 papers were identified 
using these criteria. Studies were then excluded if they only provided estimates for 
specific Hib-related syndromes as opposed to all IHiD, estimates for U5s were not 




insufficient data were reported to run at least one of the models, as described in Table 2 
below. The exclusion process is described in Appendix A. Studies with fewer than two 
years of post-vaccination data were excluded to acknowledge the disease burden curve 
and resist attributing greater direct disease reduction in younger age groups to indirect 
effects. Additionally, if multiple studies presented data from the same country for 
overlapping time periods, the study with more years of surveillance was chosen. Vaccine 
coverage level was determined as the percentage of children with three doses of Hib or 
Hib-containing vaccine; children with fewer than three doses were considered 
unimmunized. After applying these criteria, 12 studies remained and are described in 
Table 1 [3, 10, 14, 25-33]. 16 data points were abstracted from these 12 studies, as some 










































































































1998 0-59 BC 3 1 
BC = birth cohorts 
     BC + CUC = birth cohorts + catch-up campaign 





A review of the literature was commenced to identify potential methods to 
evaluate the indirect effects of Hib. A number of techniques were identified; however 
most were excluded as they required covariates that could not be obtained through a 
literature review. Three less complex methods were identified and applied to this data. 
Two of these methods were adapted from previous analyses of Hib vaccine indirect 
effects and the third from an analysis of hepatitis A vaccine rollout in the United States. 
Each method is referred to by the first author of the paper in which the method was 
proposed. The parameters necessary to run each model are included in Table 2. It was not 
possible to apply all methods to all studies due to the availability of the data needed for 
each model; however, all methods were applied to at least three point estimates. These 
methods were then compared to decide which method most completely captured the 
indirect effects of Hib vaccination. Analyses were completed in STATA (Version 13.0, 
StataCorp, College Station, Texas). 
Wolfson method- In the previous GBD study, IHiD reduction in mature 
vaccination programs, defined as those in place for more than a year, was regressed 
against vaccine coverage in U5s to understand how indirect effects changed as 
population-level coverage increased [5]. We took a similar approach with this analysis, 
but instead ran a censored regression to account for the restriction of the outcome 
variable, percent of IHiD reduction, between 0% and 100% [34]. We also defined mature 
programs as those with at least two years of post-rollout data as opposed to one year. The 
censored regression, which accounted for direct and indirect vaccine effects, was then 




were modeled by a Y = 0.95X line, as Hib vaccine is assumed to have 95% efficacy so 
95% of those vaccinated (X) would be protected against IHiD (Y) [2]. Greater disease 
reduction beyond this threshold could be attributed to indirect effects of the vaccination. 
The slope of the overall disease reduction curve was strongly positive before 50% 
coverage but was closer to zero after this point, so a spline term was fit to better represent 
the curve. By comparing the reduction of disease that had been observed in vaccine 
impact studies to what would be expected based solely on direct effects of the 
vaccination, we were able to derive an indirect effects multiplier as a function of vaccine 
coverage.  
Samandari method- Originally, this method was used to examine the indirect 
effects of routine hepatitis A vaccine rollout in the United States. A series of equations 
were proposed to measure the indirect protection found in different age groups, as the 
vaccine was approved for 2-18 year olds but disease reduction was seen in all age groups 
[35]. To assess the indirect effects seen in the unvaccinated members of the age group 
that was being vaccinated, Samandari et al provided the equation of  
I = I0 (1 - v)
C
 
In this model, I represented the disease incidence after vaccination rollout, I0 the 
incidence before vaccination rollout, v the population-level vaccine coverage, and c the 
indirect effect multiplier. The interpretation of the multiplier was described as the number 
of children who were effectively protected for each child that was vaccinated. A c of two 
indicated that two people were effectively protected for each person vaccinated, the 
person vaccinated and one unvaccinated person. For this analysis, the c coefficient was 




rate ratio. The estimated IHiD reduction was then derived from the incidence rate ratio 
and compared to the vaccine direct effect estimate to calculate the indirect effect 
multiplier. 
Adegbola method- This method was used to examine the indirect effects of Hib 
vaccine in The Gambia when routine immunization was rolled out in 1997. In order to 
distinguish the indirect effects from the direct effects of the vaccine, Adegbola et al 
developed a novel method of calculating vaccine effective coverage that would account 
for the age distribution of Hib disease in order to estimate how many children were 
vaccinated early enough to avoid disease [10]. Instead of the standard vaccine effective 
coverage equation of vaccine efficacy * vaccine coverage, they proposed replacing 
vaccine coverage with the proportion of cases that would have received direct protection 
from vaccination early enough to protect against IHiD. This figure was estimated by 
calculating the proportion of children who were protected through vaccination (with 
protection deemed complete two weeks after the second dose of Hib vaccine, the point 
where the vaccine is considered to be effective) before the average age of IHiD invasive 
disease. The new vaccine effective coverage was then used to calculate the indirect effect 
multiplier, assumed to be constant across vaccine coverage levels.  
Table 2 Parameters Necessary for Inclusion in Each Model 
Analysis Name Data Needed 
Wolfson method 
Vaccine coverage 
Percent IHID reduction 
Samandari method 
Vaccine coverage 
Pre-vaccination IHiD incidence 
Post-vaccination IHID incidence 
Adegbola method 
Average age at second dose 
Vaccine efficacy 




Imputation of Model Parameters 
Some model parameters were not explicitly stated in the studies and had to be 
imputed from various other, reliable sources. Vaccine coverage levels in U5s were very 
rarely given and often had to be calculated. Most commonly coverage levels were given 
for children under the age of 1, so U5 coverage was estimated by multiplying this 
coverage by the number of years that Hib vaccine had been universally given. For 
example, if coverage was 97% and routine vaccination had been ongoing for three years, 
the vaccine coverage for U5s was 58.2% [0.97*(3/5)]. National vaccine coverage 
estimates provided in the study papers was corroborated with what was reported by WHO 
and UNICEF to ensure accuracy of results [36]. WHO/UNICEF used surveys reporting 
on the immunization status of children 12-23 months of age to reflect coverage in the 
previous year’s birth cohort [37]. IHiD reduction was calculated using a percent change 
formula ([pre-vaccination rate- post-vaccination rate]/pre-vaccination rate * 100). These 
estimates were then checked against the papers that provided IHiD reduction estimates 
and were identical. 
Model Validation and Sensitivity Analyses 
A theoretical modelling framework for the analysis of infectious diseases was 
used to validate the results provided by the three models. Following the principles of an 
SIR model, Haber et al used vaccine coverage and attack rates in vaccinated and 
unvaccinated individuals to estimate the basic reproductive number and the reduction of 
the transmission probability due to direct and indirect effects separately [38]. These 
parameters were then used to calculate the risk of developing IHiD in the absence and 




used the results of two randomized control trials (RCTs) assessing Hib vaccine efficacy 
to calculate the proportion of disease reduction due to indirect effects and indirect effect 
multiplier at 10% increments of vaccine coverage. The results were them compared to the 
outcomes of the Wolfson, Samandari, and Adegbola methods.  
The two RCTs chosen were conducted on the Navajo Nation in the Southwestern 
United States and Finland, two settings with distinct Hib epidemiology [39, 40]. Two 
RCTs were used as this theoretical framework had not previously been applied to data 
(personal communication), so it was deemed prudent to ensure that consistent estimates 
of the indirect effect multiplier were given for separate trials of the same vaccine. 
Additionally, a “leave one out” sensitivity analysis was performed to ascertain if any 
single study had an outsized influence on the results. This was done by examining the 
magnitude of change in the average U5 vaccine coverage as each study was 
systematically removed from the calculation.  
Comparison Paper  
 One paper was found to have empirically estimated the indirect effects of Hib 
vaccine for individuals in an American Indian population [16]. The outcomes from our 
analysis were compared to the results found in the Moulton et al analysis to understand 
which model most closely approximated the individual indirect effects. This allowed for 
a better understanding of how population-level observational studies can be best used in 
the future to approximate the indirect effect results that previously could have only been 






Wolfson method- This method showed significant indirect effects at relatively low 
vaccine coverages, as can be seen in Figure 1. In vaccine coverage levels less than 40%, 
the percentage IHiD reduction was about twice as great as would be expected due to 
direct effects alone, after which the indirect effects decreased. This translated into a 
multiplier ranging from two to four at lower vaccination coverages and then decreasing to 
about one at higher coverages, indicating that indirect effects for Hib vaccine can start to 
take hold at coverage levels as low as 10%. Overall, a disease reduction of 85% was seen 
for vaccine coverage in U5s of 58%. This equation was used to calculate the expected 
IHiD at specific vaccine coverage levels: 
        For X < 50, Y = (X*1.229922) + 25.58033 





Figure 1 Estimated Disease Reduction Due to Indirect Effects- Wolfson 
 
Samandari method- Under these assumptions, indirect effects played a much 
larger role in disease reduction at lower vaccine coverage than higher coverage levels. To 
calculate the value of c, the model predicted an equation of 
c = e ^((x* -0.0221966) + 2.241278) 
This resulted in a c statistic of five or higher for vaccine coverage of 0-30%, 
rapidly decreasing to below two at 70% coverage and above.  The incidence rate ratio and 
indirect effect multiplier were then calculated. At 10% coverage, the multiplier was 
estimated to be about six, indicating that five unvaccinated individuals were protected for 
every vaccinated individual; this decreased to about one at 70% coverage and higher as 
direct effects began to dominate. A multiplier of 1.1 at 100% coverage was seen due to 
imperfect vaccine protection. The estimated IHiD reduction was calculated based on 
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reduction at 30% coverage as shown in Figure 2. After this threshold, the predicted IHiD 
reduction increased slowly until reaching 100% reduction at 100% coverage.   
Figure 2 Estimated Disease Reduction Due to Indirect Effects- Samandari 
 
Adegbola method- Using this method to alternatively calculate the proportion of 
children directly protected by vaccination, a constant indirect effect multiplier was 
calculated. Because only three studies provided the necessary parameters for this model, 
we derived a single multiplier without allowing for variation with vaccine coverage. On 
average, 30% of children were directly protected from IHiD by vaccination, indicating 
that the other 70% of disease reduction was due to indirect effects. This resulted in an 
indirect effect multiplier of 3.3, implying that the majority of protection against IHiD was 
from indirect effects. Using this multiplier, the model predicted that all IHiD should be 
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Figure 3 Estimated Disease Reduction Due to Indirect Effects- Adegbola 
 
At the same level of vaccine coverage, the three models provided varying 
estimates for the predicted IHiD reduction and indirect effect multiplier. For example at 
20% coverage, the predicted IHiD reduction ranged from 50% to almost 75%. These 
results are presented in Tables 3 and 4 respectively. Although the same trends are 
reflected in each model as seen in Figure 4, the Wolfson and Samandari methods provide 
similar IHiD reduction estimates whereas the Adegbola method predicts total disease 
elimination at much lower vaccine coverage levels. While the Wolfson method never 
reaches 100% disease reduction, both the Samandari and Adegbola methods do, though at 
very different coverage levels. The Adegbola method also overestimated the observed 
data. The indirect effect multiplier estimate varied between the methods as well. While 
both the Wolfson and Samandari multiplier start higher and decrease to around one at 




















0 10 20 30 40 50 60 70 80 90 100
Vaccine Coverage Under 5 (%)  
Observed IHiD Reduction- Total




three. The Wolfson and Samandari multipliers similarly average out to about two across 
all vaccine coverage, but the Adegbola multiplier is almost double that. 
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Table 3 Comparison of the Predicted IHiD 









10% 37.9 54.8 31.6 
20% 50.2 74.0 63.3 
30% 62.5 82.2 94.9 
40% 74.8 86.2 100.0 
50% 87.1 88.3 100.0 
60% 89.0 89.7 100.0 
70% 90.9 90.9 100.0 
80% 92.8 92.3 100.0 
90% 94.7 94.7 100.0 




Model Validation and Sensitivity Analyses 
 The Haber et al study provided similar estimates of the indirect effect multiplier 
to the three methods analyzed here, as shown in Table 4. Both studies analyzed with the 
Haber et al method produced similar multipliers at varying coverage, indicating the utility 
of the Haber method as a validation tool. These results were most similar to the Wolfson 
and Samandari methods, though they also mirrored the outcomes of the Adegbola method 
at vaccine coverage below 20%. The pattern of a higher multiplier at lower vaccine 
coverage slowly converging to a multiplier of approximately one at higher coverage 
levels as direct effects prevail was also observed with the Haber analysis, though these 
studies reached a multiplier of one at lower coverage levels than the three analysis 
methods. A comparison of the indirect effect multipliers from the different methods is 
shown in Figure 5. 














10% 4.0 5.8 3.3 5.6 4.8 
20% 2.6 3.9 3.3 2.7 2.5 
30% 2.2 2.9 3.3 1.8 1.6 
40% 2.0 2.3 3.3 1.3 1.2 
50% 1.8 1.9 3.3 1.0 1.0 
60% 1.6 1.6 3.3 1.0 1.0 
70% 1.4 1.4 3.3 1.0 1.0 
80% 1.2 1.2 3.3 1.0 1.0 
90% 1.1 1.1 3.3 1.0 1.0 
100% 1.0 1.1 3.3 1.0 1.0 
* Using Santosham et al study 
   ** Using Eskola et al study 




Figure 5 Indirect Effect Multiplier- All Methods 
 
From the “leave one out” sensitivity analysis, one estimate was identified as 
overly influential of the results. Compared to the overall average U5 vaccination 
coverage of 58%, excluding the Cowgill et al estimate for two years of post-vaccination 
data decreased the average U5 vaccination coverage to 20%. However, the Cowgill et al 
study provided two additional estimates for three and four years of post-vaccination data 
that were used in the models and were not excessively influential on the results. The CDC 
study was the least influential, decreasing the average U5 vaccination coverage to 53% 
from 58%.  
Model Results and the Comparison Paper 
 In their analysis of Hib vaccine herd effects in Navajo children, Moulton et al. 
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in children under the age of two [16]. Using 20% vaccine coverage increments, they 
observed significant risk reductions for children living in areas with 20-39% coverage 
and 40-59% coverage when compared to those living in areas with < 20% coverage. In 
areas with greater than 60% coverage, they saw a large increase in IHiD risk, though this 
was not statistically significant and attributed to a dearth of cases in high coverage 
settings. It was expected that our analysis would provide slightly lower risk reductions 
because of our focus on U5s as opposed to children under the age of two years. The 
Wolfson and Samandari methods produced similar risk reductions to the Moulton method 
below 60% vaccinated, but the Adegbola method predicted much greater reductions as 
seen in Table 5. As the Moulton paper empirically investigated the indirect protection 
provided by communities to individuals, the results are most likely a good estimator of 
the true risk reduction associated with vaccination.  











20-39% 56.5 44.0 55.5 73.1 
40-59% 73.2 78.6 69.2 100.0 
60-79% -167 85.5 76.4 100.0 








 Indirect effects have long been observed with vaccine programs, but are rarely 
measured. As this type of research is sparse, it was deemed necessary to compare 
different analytic methods and identify the ones that best approximated the disease 
reduction seen in real-world vaccine rollout scenarios. Multiple validation techniques and 
sensitivity analyses were also employed to ensure that the methods were correctly 
capturing the relationship between vaccine coverage and indirect protection. After 
searching the literature, we identified four methods that had previously been used to 
analyze primary data to better understand the impact of indirect effects on total immunity. 
Three of these methods were used in the original analysis, while the final method, a 
theoretical framework, was used for validation.  
All three of the methods used here were created to model infectious diseases that 
have high incidence in children. However the Samandari and Adegbola methods were 
developed to examine individual level data, not the group level data that we were using 
for this analysis. The Wolfson method was specifically developed for this type of data. 
Looking at Figures 4 and 5, it seems that all of the methods, with the exception of the 
Adegbola method, produced similar results. Although each method was developed with 
different assumptions and dynamics in mind, the Wolfson and Samandari methods 
estimated indirect effects similarly.  
Each of the models has strengths and weaknesses, but it seems that the Wolfson 
and Samandari methods most accurately measured indirect effects, as judged by their 
similarity to the Moulton estimates. The parameters needed for both methods are minimal 




of both of these methods. It seems likely that the two methods could be applied in 
different settings. Because the Wolfson method requires multiple pre-post studies, this 
could be a useful method to assess indirect effects in vaccines that are already being used. 
The Samandari method could alternatively be helpful in a setting where a vaccine 
program is being implemented for the first time.  
One of the most striking aspects of this analysis is the existence of significant 
indirect protection at low levels of vaccine coverage. While most vaccines likely provide 
some degree of indirect protection at low vaccine coverage due to the reduction in the 
pool of susceptibles, it is negligible on a population level [41]. However, the ability of 
Hib conjugate vaccine to reduce nasopharyngeal colonization leads to significant indirect 
protection, providing noticeable protection at low vaccine coverage. These low levels of 
coverage can easily be achieved through private market introduction without routine 
vaccination and has been shown to lead to drastic disease reductions; this is despite low 
coverage and better risk profile of vaccine recipients in exclusively private market 
settings [14].  
Strengths and Limitations 
This analysis had a number of strengths that increased both the reliability and 
validity of the results. Twelve studies were included from many parts of the world, with 
only four from the United States and Western Europe. Previous analyses of vaccines have 
focused exclusively on these high-income, low-burden settings, drawing concerns about 
their external validity. Post-vaccination data also ranged from two to nineteen years after 
introduction into routine vaccination programs, representing almost the entire time since 




as well as validation and the results of the sensitivity analysis, increase confidence that 
the results may reflect the reality of indirect protection from Hib conjugate vaccine.   
Despite these strengths, there are a number of limitations that could have affected 
our final results. Incidence rates are almost certainly underestimated in all of these 
studies, as they did not capture infections that were not seen in healthcare facilities.  
However, it is likely that incidence was underestimated both before and after vaccine 
introduction, so calculated disease reduction is likely to be less biased. There was also 
some discrepancy between models regarding the level of vaccine coverage required for 
IHiD elimination, with most estimating that almost 100% coverage would be necessary to 
completely eliminate disease. However, in practice we have seen complete elimination of 
disease with coverage levels as low as 60%, and our models indicate greater than 90% 
disease reduction at 60% coverage [10]. This difference could be due to the lack of 
studies with less than 20% coverage and only four estimates with coverage below 40%. 
Although our exclusion of studies with few years of post-vaccination data was necessary 
to account for the disease burden curve, this could have biased our results.  
The need to assess indirect effects over years of rollout leaves open the possibility 
that IHiD reduction could be due, at least in part, to secular trends. Fortunately, many 
studies acknowledged this possibility and also tracked rates of invasive pneumococcal 
disease in settings where the pneumococcal conjugate vaccine had not yet been 
introduced. They did not observe significant changes in pneumococcal disease during the 
time period of rapid IHiD disease reduction, indicating that secular trends did not play a 
large role in disease reduction. The small number of studies also precluded us from 




estimates, though we did examine the changes in standard error with the “leave one out” 
analysis.  
Future Directions 
Overall, this analysis has a number of real world and future research implications. 
Currently, critical vaccination thresholds used for disease elimination estimates are 
calculated as 1 – 1/R0 [12, 41]. However the value of R0 is theoretical and difficult to 
conclusively determine. Using the methods described here, a critical vaccination 
threshold could be estimated based on real world data, leading to a more accurate idea of 
the level of vaccination necessary to achieve Hib elimination. This would allow for more 
efficient allocation of resources to vaccination programs. The methods used here could 
also be applied to other vaccines, such as pneumococcal conjugate vaccine, to better 
understand the indirect protection provided and more accurately estimate the population 
protection provided by these vaccines. A better understanding of the full protection of 
vaccinations will allow policy makers to more confidently invest in vaccination 
programs. It is evident from our analysis that significant disease reduction is possible 
without prohibitively high vaccine coverage figures. We hope that these estimates will 
encourage policy makers to make decisions that will drastically decrease, and eventually 
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